期刊文献+

HIV-1 HXB2株ta(tB41-101N)融合基因原核表达质粒的构建及表达

Construction and Expression of Prokaryotic Expression Vector for tat (B41-101N)Fusion Gene of HIV-1 HXB2 Strain
原文传递
导出
摘要 目的构建HIV-1HXB2株ta(tB41-101N)融合基因原核表达质粒,表达并纯化Ta(tB41-101N)融合蛋白,为进一步研究其免疫原性奠定基础。方法在HIV-1HXB2株天然Tat蛋白N-端添加Tat41-101位氨基酸(aa),采用PCR法从HIV-1HXB2株tat基因中扩增分别编码Tat41-101aa和Tat1-101aa的tat41-101和tat1-101两个基因片段,重叠延伸PCR法扩增其融合基因ta(tB41-101N),并构建其原核表达质粒pET32a-ta(tB41-101N),经双酶切及测序验证后,转化大肠杆菌BL21(DE3),IPTG诱导表达。融合蛋白经Ni2+-NTA柱亲和层析纯化后,进行SDS-PAGE、Westernblot及ELISA鉴定。结果重叠延伸PCR扩增出约500bp的ta(tB41-101N)融合基因,酶切及测序结果表明重组表达质粒pET32a-ta(tB41-101N)构建正确。SDS-PAGE分析显示,表达的Ta(tB41-101N)融合蛋白相对分子质量约为36000,约占菌体总蛋白的7%,纯化后纯度约为60%;Westernblot和ELISA分析显示,Ta(tB41-101N)融合蛋白与小鼠抗Tat单抗及抗-HIV阳性血清(抗Tat抗体阳性)均呈特异性阳性反应。结论已成功构建了HIV-1HXB2株ta(tB41-101N)融合基因原核表达质粒,并表达了其融合蛋白,该蛋白较好地保留了天然Tat蛋白的免疫反应性,为Tat新型疫苗的研究奠定了基础。 Objective To construct the prokaryotic expression vector for tat(B41-101N)fusion gene of HIV-1 HXB2 strain, express and purify Tat (B41-101N)fusion protein and lay a foundation of study on its immunogenicity. Methods Tat41-101 amino acids(aa)were added to the N-terminus of Tat protein of native HIV-1 HXB2 strain. The tat41-101 and tat1-101 gene fragments, encoding Tat41-101aa and Tat1-101aa respectively, were amplified by PCR and used to generate fusion gene tat(B41-101N)by splicing by overlap extension PCR (SOE PCR). Prokaryotic expression vector pET32a-tat (B41-101N) was constructed and identified by restriction analysis and sequencing, then transformed to E. coli BL21 (DE3) for expression under induction of IPTG. The expressed filsion protein Tat (B41-1OIN) was purified by Ni2+-NTA column affinity chromatography and identified by SDS-PAGE, Western blot and EI,ISA. Results The fusion gene tat(B41-101N) at a length of about 500 bp was amplified by SOE PCR. Recombinant ptasmid pET32a-tat (B41-101N) was proved to be constructed correctly by both restriction analysis and sequencing. SDS-PAGE showed that Tat (B41-101N ) fusion protein, with a relative molecular mass of about 36 000, was expressed, which contained about 7% of total somatic protein and reached a purity of about 60% 'after purification. Tat( B41-101N ) fusion protein showed specific reaction with mouse McAb against Tat and anti-HIV positive sera, as proved by Western blot and ELISA. Conclusion The prokaryotic expression vector for tat (B41-101N) fusion gene of HIV-I HXB2 strain was successfully constructed, and the fusion protein with immunoreactivity of native Tat protein was expressed, which laid a foundation of further study on novel HIV Tat vaccine.
出处 《中国生物制品学杂志》 CAS CSCD 2009年第11期1049-1053,共5页 Chinese Journal of Biologicals
基金 国家自然科学基金资助项目(30872246 30872405) 国家"863"项目(2006AA02A238) 上海市基础研究重点项目(08JC1405200)
关键词 HIV-1 TAT蛋白 融合蛋白 原核表达 重叠延伸PCR HIV-1 Tat protein Fusion protein Prokaryotic expression SOE PCR
  • 相关文献

参考文献14

  • 1Apolloni A, Hooker C W, Mak J . et al. Human immunodeficiency virus type 1 protease regulation of tat activity is essential for efficient reverse transcription and replication. J Virol, 2003, 77 (18): 9912-9921. 被引量:1
  • 2Aoki Y, Tosato G. HIV-I Tat enhances Kaposi sarcoma associated herpesvirus (KSHV) infectivity. Blond, 2004, 104 (3): 810-814. 被引量:1
  • 3Wallace DR. HIV neurotoxicity: potential therapeutic interventions. J Biomed Biotechnol, 2006, 2006 (3): 65741. 被引量:1
  • 4艾菁,王丽梅,夏威,耿美玉.Tat蛋白结构与功能的研究进展[J].细胞与分子免疫学杂志,2005,21(B03):133-135. 被引量:17
  • 5Jeang KT, Xiao H, Rich EA. Muhifaceted activities of the HIV-I transactivator of transcription, Tat J Biol Chem, 1999, 274 (41): 28837-28840. 被引量:1
  • 6Ensoli B, Fiorelli V, Ensoli F, et al. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS, 2006, 20 ( 18): 2245-2261. 被引量:1
  • 7Belliard G, Hurtrel B, Moreau E, et al. Tat-neutralizing versus Tatprotecting antibodies in rhesus macaques vaccinated with Tat peptides. Vaccine, 2005, 23 ( 11 ): 1399-1407. 被引量:1
  • 8Tikhonov I, Ruckwardt TJ, Hatfield GS, et al. Tat-neutralizing antibodies in vaccinated macaques. J Virol, 2003, 77(5 ): 3157-3166. 被引量:1
  • 9Zagury JF, Sill A, Blattner W, et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat Toxoid as an HIV-1 vaccine. J Hum Virol, 1998, 1 (4): 282-292. 被引量:1
  • 10Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: the human immunodeficieney virus(HIV).Vaccine, 2006, 24 (19): 4062-4081. 被引量:1

二级参考文献35

  • 1林剑萍,王华,王玲,卫红飞,胡晓平,王丽颖,于永利.HIV-1Tat基因的融合构建及在大肠杆菌中的高效表达[J].细胞与分子免疫学杂志,2005,21(1):33-36. 被引量:6
  • 2艾菁,王丽梅,夏威,耿美玉.Tat蛋白结构与功能的研究进展[J].细胞与分子免疫学杂志,2005,21(B03):133-135. 被引量:17
  • 3齐香荣,张相民,高瑛瑛,邓瑶,闫克夏,李仁清,阮力.HIV-1 tat基因改造及其蛋白表达、纯化与抗体制备[J].生物技术通讯,2006,17(2):142-145. 被引量:5
  • 4Apolloni A. Hooker CW, Mak J, et al. Human immunodeficiency virus type 1 protease regulation of tat activity is essential for efficient reverse transcription and replication. J Virol, 2003, 77 (18) : 9912-9921. 被引量:1
  • 5Li CJ, Friedman D J, Wang C, et al. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science, 1995, 268 (5209) : 429-431. 被引量:1
  • 6Aoki Y, Tosato G. HIV-1 Tat enhances Kaposi sarcoma associated herpesvirus ( KSHV ) infectivity. Blood, 2004, 104 ( 3 ) : 810-814. 被引量:1
  • 7Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem, 1999, 274 (41): 28837-28840. 被引量:1
  • 8Ensoli B, Fiorelli V, Ensoli F, et al. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS, 2006, 20(18) : 2245-2261. 被引量:1
  • 9Zagury JF, Sill A, Blattner W, et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol, 1998, 1 (4) : 282-292. 被引量:1
  • 10Belliard G, Hurtrel B, Moreau E, et al. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides. Vaccine, 2005, 23 ( 11 ) : 1399-1407. 被引量:1

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部